𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Plasma cell leukemia: advantages of treatment with bortezomib

✍ Scribed by N. Fraimout; B. Kadouch; M. Ticchioni; N. Mounier

Publisher
Springer-Verlag
Year
2008
Tongue
English
Weight
73 KB
Volume
3
Category
Article
ISSN
1776-2596

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of bortezomib in pat
Efficacy and safety of bortezomib in patients with plasma cell leukemia
✍ Pellegrino Musto; Fausto Rossini; Francesca Gay; Vincenzo Pitini; Tommasina Gugl πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The prognosis of patients with plasma cell leukemia (PCL), an aggressive variant of multiple myeloma (MM), is usually poor. Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of borte

Bortezomib is an efficient agent in plas
Bortezomib is an efficient agent in plasma cell leukemias
✍ Azucena EsparΓ­s-Ogando; AdriΓ‘n Alegre; Beatriz Aguado; Gema Mateo; Norma GutiΓ©rr πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 128 KB

## Abstract Plasma cell leukemia (PCL) represents the most aggressive form of monoclonal gammopathy for which new treatment approaches are needed. Here we report the effect of Bortezomib on cells from 4 patients with PCL, as well as the __in vivo__ efficacy on a patient with secondary PCL. Bortezom

Plasma cell leukemia with myelofibrosis
Plasma cell leukemia with myelofibrosis
✍ T. Murayama; T. Matsui; Y. Hayashi; T. Taniguchi; M. Ito; T. Natazuka; S. Imoto; πŸ“‚ Article πŸ“… 1994 πŸ› Springer 🌐 English βš– 465 KB